[The immunomodulator ximedon lowers the level of induced DNA damages in bone marrow and peripheral blood cells: the possibilities for immunogenetic correction].
It was established in experiments on albino unbred mice and during treatment of patients with osteomyelitis that 30 mg/kg of ximidon suppresses the formation of micronuclear polychromatophilic erythrocytes found in the bone marrow of mice and peripheral blood of patients with chronic osteomyelitis. The interrelationship of the results obtained with the modulating effect of ximidon on the mitochondrial, thiol, and adenylate cyclase-dependent mechanisms of cell regulation is discussed.
Cherepnev
G V
GV
Research Department, Republican Medical Diagnostic Center, Kazan, Russia.
Tereshchenko
V Iu
VIu
Malyshev
K V
KV
Semenov
V V
VV
Slabnov
Iu D
IuD
Garaev
R S
RS
D010129:4-Aminobenzoic Acid / Q000494:pharmacology; D000276:Adjuvants, Immunologic / Q000494:pharmacology* / Q000627:therapeutic use; D000328:Adult; D000818:Animals; D001854:Bone Marrow Cells / Q000187:drug effects*; D016009:Chi-Square Distribution; D002908:Chronic Disease; D004247:DNA / Q000187:drug effects*; D004249:DNA Damage / Q000187:drug effects*; D004912:Erythrocytes / Q000187:drug effects*; D006801:Humans; D008297:Male; D051379:Mice; D015162:Micronucleus Tests / Q000379:methods / Q000706:statistics & numerical data; D016685:Mitomycin; D019384:Nucleic Acid Synthesis Inhibitors; D010019:Osteomyelitis / Q000097:blood / Q000188:drug therapy; D011743:Pyrimidines / Q000494:pharmacology* / Q000627:therapeutic use
D000276:Adjuvants, Immunologic; D019384:Nucleic Acid Synthesis Inhibitors; D011743:Pyrimidines; C069705:xymedon; D016685:Mitomycin; D004247:DNA; D010129:4-Aminobenzoic Acid